Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | HTR2B | P41595 | 2/20 | 0.49 |
| ▸ | STK33 | Q9BYT3 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CXCR6 | O00574 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3199346 | 0.99 | GRM5 (0.53) | GRM5ALDH1A1L3MBTL1HTR2BSTK33 | |
| SCHEMBL3199520 | 0.85 | ALDH1A1 (0.48) | ALDH1A1HTR2BSMN1; SMN2CXCR6 | |
| SCHEMBL13490630 | 0.83 | SMYD3 (0.56) | HTR2BSMN1; SMN2 | |
| SCHEMBL13490663 | 0.83 | SMN1; SMN2 (0.47) | HTR2BSMN1; SMN2CXCR6 | |
| Hydrochloric Acid SCHEMBL3224400 | 0.82 | SMYD3 (0.55) | HTR2BSMN1; SMN2 | |
| SCHEMBL14192836 | 0.82 | CHEK1 (0.46) | HTR2BSMN1; SMN2CXCR6 | |
| SCHEMBL13490684 | 0.81 | EPHX2 (0.50) | HTR2BSMN1; SMN2MEN1KMT2ACXCR6 | |
| SCHEMBL13490400 | 0.81 | HTR2B (0.56) | GRM5ALDH1A1HTR2BSTK33SMN1; SMN2 | |
| SCHEMBL13490398 | 0.81 | SMN1; SMN2 (0.45) | GRM5L3MBTL1HTR2BSMN1; SMN2 | |
| SCHEMBL3222424 | 0.81 | NPC1 (0.60) | L3MBTL1HTR2BSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029615-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. | 2010-02-04 | — | — | US | disclosed |
| US-20100029615-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029615-A1 | BENZIMIDAZOLE DERIVATIVES | ACIN1, HAT1, CCNE1 | GRM5 4172/4885ALDH1A1 680/4885L3MBTL1 717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.